Tumor suppressor CAR-1

• US 7,169,384 B2
• Filed: 06/15/2005
• Issued: 01/30/2007
• Est. Priority Date: 08/10/2000
• Status: Expired due to Fees

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Killary, Ann, Lott, Steve, Chandler, Dawn
• Primary Examiner(s): WHITEMAN, BRIAN A
• Application Number:
  US11/153,238
• Publication Number:
  US 20060019281A1
• Time in Patent Office: 594 Days
• Field of Search: 424/93.2
• US Class Current: 424/93.2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4703 Inhibitors; Suppressors

Abstract

The present invention relates to a new tumor suppressor, designated CAR-1, the gene for which is located on the short arm of human chromosome 1. This gene is directly implicated in colon, kidney and breast cancers, and the CAR-1 ubiquitous expression of the corresponding transcript suggests that it may be involved in yet others. Thus, one aspect of the invention is the diagnosis of CAR-1-related malignancies. The full length cDNA for CAR-1, as well as oligonucleotides derived therefrom, are disclosed. Screening methods for modulators of CAR-1 function and expression, as well as methods for cancer therapy, are described.

Claims

1. A method for suppressing growth of a cancer cell comprising directly contacting said cell with an expression cassette comprising a polynucleotide encoding a polypeptide having the sequence of SEQ ID NO:

1 or SEQ ID NO;

2, wherein said polynucleotide is under the control of a promoter operable in eukaryotic cells.

2. The method of claim 1, wherein said promoter is heterologous to the polynucleotide sequence.

3. The method of claim 2, wherein said promoter is selected from the group consisting of hsp68, SV40, CMV, MKC, GAL4_UAS, HSV and β

-actin.

4. The method of claim 2, wherein said promoter is a tissue specific promoter.

5. The method of claim 2, wherein said promoter is an inducible promoter.

6. The method of claim 2, wherein said expression cassette is contained in a viral vector.

7. The method of claim 6, wherein said viral vector is selected from the group consisting of a retroviral vector, an adenoviral vector, and adeno-associated viral vector, a vaccinia viral vector, and a herpesviral vector.

8. The method of claim 1, wherein said expression cassette further comprises a polyadenylation signal.

9. The method of claim 1, wherein said expression cassette comprises a second polynucleotide encoding a second polypeptide.

10. A method for altering the phenotype of a tumor cell comprising the step of directly contacting the cell with a nucleic acid comprising (i) a region encoding a tumor suppressor designated CAR-1 having the sequence of SEQ ID NO:

1 or SEQ ID NO ;

2 and (ii) a promoter active in said tumor cell, wherein said promoter is operably linked to the region encoding said tumor suppressor, under conditions permitting the uptake of said nucleic acid by said tumor cell.

11. The method of claim 10, wherein said tumor cell is derived from a tissue selected from the group consisting of brain, lung, liver, spleen, kidney, lymph node, small intestine, blood cells, pancreas, colon, stomach, breast, endometrium, prostate, testicle, ovary, skin, head and neck, esophagus, bone marrow and blood tissue.

12. The method of claim 11, wherein the phenotype is selected from the group consisting of apoptosis, angiogenesis, proliferation, migration, contact inhibition, soft agar growth or cell cycling.

13. The method of claim 11, wherein said nucleic acid is encapsulated in a liposome.

14. The method of claim 11, wherein said nucleic acid is a viral vector selected from the group consisting of retrovirus, adenovirus, adeno-associated virus, vaccinia virus and herpesvirus.

15. The method of claim 14, wherein said nucleic acid is encapsulated in a viral particle.

16. A method for treating a subject with cancer comprising the step of directly administering to a cancer cell in said subject a nucleic acid comprising (i) a region encoding a tumor suppressor designated CAR-1 having the sequence of SEQ ID NO:

1 or SEQ ID NO;

2 and (ii) a promoter active in eukaryotic cells, wherein said promoter is operably linked to the region encoding said tumor suppressor.

17. The method of claim 16, wherein said cancer cell is derived from a tissue selected from the group consisting of brain, lung, liver, spleen, kidney, lymph node, small intestine, blood cells, pancreas, colon, stomach, breast, endometrium, prostate, testicle, ovary, skin, head and neck, esophagus, bone marrow and blood tissue.

18. The method of claim 16, wherein the subject is a human.